Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

被引：0
|
作者：
Claudia A. Chiriboga
Claudio Bruno
Tina Duong
Dirk Fischer
Eugenio Mercuri
Janbernd Kirschner
Anna Kostera-Pruszczyk
Birgit Jaber
Ksenija Gorni
Heidemarie Kletzl
Imogen Carruthers
Carmen Martin
Francis Warren
Renata S. Scalco
Kathryn R. Wagner
Francesco Muntoni
机构：
[1] Columbia University Irving Medical Center,Department of Neurology
[2] University of Genoa,Centre of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health
[3] Stanford University,DINOGMI
[4] University Children’s Hospital Basel,Department of Neurology
[5] University of Basel,Division of Neuropediatrics
[6] Fondazione Policlinico Gemelli IRCCS,Pediatric Neurology Institute, Catholic University and Nemo Pediatrico
[7] Medical Center-University of Freiburg,Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine
[8] Medical University of Warsaw,Department of Neurology
[9] ERN EURO-NMD,Roche Pharmaceutical Research and Early Development
[10] Pharma Development,Product Development Neuroscience
[11] Safety,The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre
[12] F. Hoffmann-La Roche Ltd,undefined
[13] PDMA Neuroscience and Rare Disease,undefined
[14] F. Hoffmann-La Roche Ltd,undefined
[15] Roche Innovation Center Basel,undefined
[16] Roche Products Ltd,undefined
[17] F. Hoffmann-La Roche Ltd,undefined
[18] Great Ormond Street Institute of Child Health University College London,undefined
[19] and Great Ormond Street Hospital Trust,undefined
来源：
Neurology and Therapy | 2023年 / 12卷
关键词：
Evrysdi; Pharmacodynamics; Risdiplam; Safety; Spinal muscular atrophy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [31] JEWELFISH: 24-month Safety, Pharmacodynamic and Exploratory Efficacy Data in Non-Treatment-Naive Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam
    Chiriboga, Claudia
    Bruno, Claudio
    Duong, Tina
    Fischer, Dirk
    Kirschner, Janbernd
    Scoto, Mariacristina
    Mercuri, Eugenio
    Gerber, Marianne
    Gorni, Ksenija
    Kletzl, Heidemarie
    Carruthers, Imogen
    Martin, Carmen
    Gidaro, Teresa
    Muntoni, Francesco
    NEUROLOGY, 2023, 100 (17)
  • [32] Budget impact analysis: comparing the costs of nusinersen and risdiplam in the treatment of type 3 spinal muscular atrophy patients
    Uda, Maria Elisabetta
    Rivano, Melania
    Aledda, Lucia
    Maioli, Maria Antonietta
    Lombardo, Fabio
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023,
  • [33] Risdiplam in Adult Patients With 5q Spinal Muscular Atrophy: A Single-Center Longitudinal Study
    Gavriilaki, Maria
    Moschou, Maria
    Pagiantza, Maria
    Arnaoutoglou, Marianthi
    Kimiskidis, Vasilios
    MUSCLE & NERVE, 2025, 71 (03) : 384 - 391
  • [34] Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
    Hahn, Andreas
    Guenther, Rene
    Ludolph, Albert
    Schwartz, Oliver
    Trollmann, Regina
    Weydt, Patrick
    Weiler, Markus
    Neuland, Kathrin
    Schwaderer, Martin Sebastian
    Hagenacker, Tim
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
  • [35] Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
    Andreas Hahn
    René Günther
    Albert Ludolph
    Oliver Schwartz
    Regina Trollmann
    Patrick Weydt
    Markus Weiler
    Kathrin Neuland
    Martin Sebastian Schwaderer
    Tim Hagenacker
    Orphanet Journal of Rare Diseases, 17
  • [36] Risdiplam real-world experience in paediatric patients with spinal muscular atrophy type 2
    Nascimento Osorio, A.
    Exposito-Escudero, J.
    Medina, J.
    Valle, M.
    Roca, S.
    Moya, O.
    Natera De-Benito, D.
    Latre, C.
    Ortez, C.
    Carrera-Garcia, L.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [37] Safety of risdiplam in spinal muscular atrophy patients after short-term treatment with nusinersen
    Yan, Yue
    Feng, Yijie
    Jiang, Liya
    Jin, Jianing
    Mao, Shanshan
    MUSCLE & NERVE, 2024, 70 (05) : 1095 - 1098
  • [38] Real-world treatment with risdiplam in adults with spinal muscular atrophy (SMA): a multicenter study
    Guittari, C.
    Candrilli, S.
    Miles, L.
    Simpson, A.
    Shapouri, S.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S164 - S164
  • [39] RAINBOWFISH: A study of risdiplam (RG7916) in infants with presymptomatic spinal muscular atrophy (SMA)
    Servais, L.
    Bertini, E.
    Al-Muhaizea, M.
    Nelson, L.
    Prufer, A.
    Vlodavets, D.
    Wang, Y.
    Zanoteli, E.
    Burke, L.
    El-Khairi, M.
    Gorni, K.
    Kletzl, H.
    Gerber, M.
    Scalco, R.
    Finkel, R.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S127 - S127
  • [40] Global Risdiplam Compassionate Use Program for Patients with Type 1 or 2 Spinal Muscular Atrophy
    Kantaria, Rakesh
    Baker, Karen
    Beckley-Kartey, Senam
    Gorni, Ksenija
    Montrocher-Ober, Isabelle
    Vindevoghel, Laurence
    CLINICAL THERAPEUTICS, 2024, 46 (04) : 374 - 378
12345